natgillin/translations-raw huggingface dataset:
14x1 tablets 28x1 tablets 30x1 tablets 40x1 tablets 56x1 tablets 60x1 tablets 84x1 tablets 90x1 tablets 98x1 tablets 100x1 tablets 
14x1 tabletti 28x1 tabletti 30x1 tabletti 40x1 tabletti 56x1 tabletti 60x1 tabletti 84x1 tabletti 90x1 tabletti 98x1 tabletti 100x1 tabletti
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. 
Aordi- või mitraalklapi stenoosi või obstruktiivse hüpertroofilise kardiomüopaatiaga patsientidele on näidustatud eriline ettevaatus, nagu teiste vasodilataatoritega.
Each tablet contains 85.6 mg sorbitol (E420) For the full list of excipients, see section 6.1. 
Üks tablett sisaldab 85,6 mg sorbitooli (E420) Abiainete täielik loetelu vt lõik 6.1.
Telmisartan Teva 80 mg Tablets Telmisartan 
Telmisartan Teva 80 mg tabletid Telmisartaan
Syncope 
Sünkoop
Telmisartan Teva 40 mg Tablets Telmisartan 
Telmisartan Teva 40 mg tabletid Telmisartaan
Telmisartan Teva is provided in peelable perforated unit-dose aluminium-aluminium blisters and perforated unit-dose aluminium-aluminium blisters containing 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tablets for each type of blister presentation, although not all pack sizes may be marketed. 
Telmisartan Teva on saadaval lahti kooritavates perforeeritud üheannuselistes blistrites ja alumiiniumalumiinium perforeeritud üheannuseliste blistrites, mis sisaldavad 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tabletti mõlemat tüüpi blistris.
Urinary tract infection including cystitis, upper respiratory tract infection including pharyngitis and sinusitis 
Kuseteede infektsioon, sh tsüstiit, ülemiste hingamisteede infektsioon, sh farüngiit ja sinusiit
Pack sizes of 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tablets for perforated blisters. 
Pakendi suurused 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tabletti perforeeritud blistrites.
Pack sizes of 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tablets for peelable perforated blisters. 
Pakendi suurused 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tabletti lahtikooritavates perforeeritud blistrites.
• Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain ‘water tablets'), ACE inhibitors, angiotensin II receptor antagonists, NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin, immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim. 
• Ravimid, mis võivad suurendada kaaliumi taset veres, nt kaaliumi sisaldavad soolaasendajad, kaaliumi säästvad diureetikumid (teatud „vett väljutavad tabletid“), AKE inhibiitorid, angiotensiin II retseptorite antagonistid, MSPVA-d (mittesteroidsed põletikuvastased ravimid, nt aspiriin või ibuprofeen), hepariin, immunosupressandid (nt tsüklosporiin või takroliimus) ja antibiootikum trimetoprim.
These pharmacologically-mediated undesirable effects, known from preclinical studies with both angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists, were prevented by oral saline supplementation. 
Prekliiniliste uuringute andmetel välditi nii angiotensiini konverteeriva ensüümi inhibiitorite kui ka angiotensiin II retseptori antagonistide poolt teadaolevalt farmakoloogiliselt indutseeritud kõrvaltoimeid füsioloogilise lahuse suukaudse manustamisega.
There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system. 
Kahepoolse neeruarteri stenoosiga patsientidel või juhtudel, kui patsiendil on ainsa funktsioneeriva neeru arteri stenoos, on reniin-angiotensiin-aldosteroon-süsteemi inhibiitorite kasutamisel suurenenud risk raske hüpotensiooni ja neerupuudulikkuse tekkeks.
Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim. 
Ravimid või ravimite terapeutilised rühmad, mis võivad esile kutsuda hüperkaleemiat on kaaliumi sisaldavad soolaasendajad, kaaliumisäästvad diureetikumid, AKE inhibiitorid, angiotensiin II retseptori antagonistid, mittesteroidsed põletikuvastased ained (MSPVA-d, sh selektiivsed COX-2 inhibiitorid), hepariin, immunosupressandid (tsüklosporiin või takroliimus) ja trimetoprim.
Each tablet contains 42.8 mg sorbitol (E420) For the full list of excipients, see section 6.1. 
Üks tablett sisaldab 42,8 mg sorbitooli (E420) Abiainete täielik loetelu vt lõik 6.1.
The incidence of dry cough was significantly lower in patients treated with telmisartan than in those given angiotensin converting enzyme inhibitors in clinical trials directly comparing the two antihypertensive treatments. 
Otseselt kahte ravi võrdlevates kliinilistes uuringutes oli telmisartaaniga ravitud patsientidel kuiva köha esinemissagedus tunduvalt väiksem kui angiotensiini konverteeriva ensüümi inhibiitoreid saanutel.
White to off white, oval shaped tablet; one side of the tablet is debossed with the number "93". 
Valge kuni valkjas ovaalse kujuga tablett; tableti ühele küljele on märgitud number „93“.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton of peelable blisters 
VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Karp lahti kooritavate blistritega
INFORMATION IN BRAILLE Telmisartan Teva 20 mg 
INFORMATSIOON BRAILLE' KIRJAS (PUNKTKIRJAS) Telmisartan Teva 20 mg
Nervous system disorders Uncommon: 
Närvisüsteemi häired Aeg-ajalt:
Each tablet contains 21.4 mg sorbitol (E420) For the full list of excipients, see section 6.1. 
Üks tablett sisaldab 21,4 mg sorbitooli (E420) Abiainete täielik loetelu vt lõik 6.1.
There is no evidence of clinically relevant accumulation of telmisartan taken at the recommended dose. 
Telmisartaani manustamisel soovitatavas ööpäevases annuses ei ole esinenud kliiniliselt olulist kumulatsiooni.
INFORMATION IN BRAILLE Telmisartan Teva 40 mg 
INFORMATSIOON BRAILLE' KIRJAS (PUNKTKIRJAS) Telmisartan Teva 40 mg
INFORMATION IN BRAILLE Telmisartan Teva 80 mg 
INFORMATSIOON BRAILLE' KIRJAS (PUNKTKIRJAS) Telmisartan Teva 80 mg
Do not take Telmisartan Teva - if you are allergic to telmisartan or any other ingredients of this medicine (listed in section 6). 
Ärge võtke Telmisartan Teva't - kui te olete telmisartaani või selle ravimi mis tahes koostisosa(de) (loetletud lõigus 6) suhtes allergiline - kui te olete rohkem kui 3 kuud rase (Samuti on parem vältida Telmisartan Teva võtmist raseduse varases järgus - vt lõik Rasedus).
Dry mouth, stomach discomfort, dysgeusia 
Suukuivus, mao häired, düsgeusia
Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. 
Rasestumist planeeriv patsient tuleb üle viia alternatiivsele antihüpertensiivsele ravile, mille ohutusprofiil raseduse korral on tõestatud, välja arvatud juhul, kui ravi jätkamist angiotensiin II retseptori antagonistiga peetakse oluliseks.
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors, and with angiotensin II receptor antagonists, including telmisartan. 
Liitiumi samaaegsel kasutamisel angiotensiini konverteeriva ensüümi inhibiitoritega - ja ka angiotensiin II retseptori antagonistidega, k.a telmisartaaniga - on täheldatud liitiumi kontsentratsiooni pöörduvat tõusu seerumis ja selle toksilisuse suurenemist.
Do not take a double dose to make up for forgotten individual doses. 
Ärge võtke kahekordset annust, kui annus jäi eelmisel korral võtmata.
Bradycardia 
Bradükardia
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 
b. Kõrvaltoimete kokkuvõte tabelina
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton of blisters 
VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Karp blistritega
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassiumsparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal antiinflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim). 
See risk võib suureneda, kui seda kombineeritakse mõne muu samuti hüperkaleemiat esile kutsuda võiva ravimiga (kaaliumi sisaldavad soolaasendajad, kaaliumisäästvad diureetikumid, AKE inhibiitorid, angiotensiin II retseptori antagonistid, mittesteroidsed põletikuvastased ained (MSPVA-d, sh selektiivsed COX-2 inhibiitorid), hepariin, immunosupressandid (tsüklosporiin või takroliimus) ja trimetoprim).
Vascular disorders Uncommon: 
Vaskulaarsed häired Aeg-ajalt:
Respiratory, thoracic and mediastinal disorders Uncommon: 
Hüpotensioon, ortostaatiline hüpotensioon Respiratoorsed, rindkere ja mediastiinumi häired Aeg-ajalt:
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 40 mg telmisartan Excipients with known effect: 
KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks tablett sisaldab 40 mg telmisartaani Teadaolevat toimet omav(ad) abiaine(d):
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg telmisartan Excipients with known effect: 
KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks tablett sisaldab 20 mg telmisartaani Teadaolevat toimet omav(ad) abiaine(d):
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 80 mg telmisartan Excipients with known effect: 
KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks tablett sisaldab 80 mg telmisartaani Teadaolevat toimet omav(ad) abiaine(d):
Symptomatic hypotension, especially after the first dose of Telmisartan Teva, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea, or vomiting. 
Patsientidel, kes saavad tugevat diureetilist ravi, on piiratud soolasisaldusega dieedil, kellel on kõhulahtisus või oksendamine, mille tagajärjel on välja kujunenud vedeliku- ja/või naatriumipuudus, võib Telmisartan Teva kasutamisel, eriti pärast esimest annust esineda sümptomaatiline hüpotensioon.
Corticosteroïds (systemic route) Reduction of the antihypertensive effect. 
Kortikosteroidid (süsteemselt)
Tell your doctor if you are breast-feeding or about to start breast-feeding. 
Kui te toidate last rinnaga või alustate rinnaga toitmist, rääkige sellest oma arstile.
Telmisartan Teva 80 mg tablets are white to off white, oval shaped tablets; one side of the tablet is debossed with the number "93". 
Telmisartan Teva 80 mg tabletid on valged kuni valkjad ovaalse kujuga tabletid; tableti ühele küljele on märgitud number „93“.
Telmisartan Teva 40 mg tablets are white to off white, oval shaped tablets; one side of the tablet is debossed with the number "93". 
Telmisartan Teva 40 mg tabletid on valged kuni valkjad ovaalse kujuga tabletid; tableti ühele küljele on märgitud number „93“.
potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal antiinflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim. 
mittesteroidsed põletikuvastased ained (MSPVA-d, sh selektiivsed COX-2 inhibiitorid), hepariin, immunosupressandid (tsüklosporiin või takroliimus) ja trimetoprim).
Prior treatment with high dose diuretics such as furosemide (loop diuretic) and hydrochlorothiazide (thiazide diuretic) may result in volume depletion, and in a risk of hypotension when initiating therapy with telmisartan. 
Telmisartaanravi alustamisega võib kaasneda veremahu vähenemine ja hüpotensiooni riski suurenemine, kui eelnevalt on raviks kasutatud diureetikumide - nt furosemiidi (lingudiureetikum) ja hüdroklorotiasiidi (tiasiiddiureetikum) - suuri annuseid.
Telmisartan Teva 20 mg tablets are white to off white, oval shaped tablets; one side of the tablet is debossed with the number "93". 
Telmisartan Teva 20 mg tabletid on valged kuni valkjad ovaalse kujuga tabletid; tableti ühele küljele on märgitud number „93“.
The blood pressure lowering effect of telmisartan can be increased by concomitant use of other antihypertensive medicinal products. 
Teiste antihüpertensiivsete ravimite samaaegne kasutamine võib tugevdada telmisartaani vererõhku langetavat toimet.
If you get any side effects,talk to your doctor or pharmacist. 
Kui teil tekib ükskõik milline kõrvaltoime, pidage nõu oma arsti või apteekriga.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 40 mg telmisartan 
TOIMEAINE(TE) SISALDUS Üks tablett sisaldab 40 mg telmisartaani
Each Telmisartan Teva tablet contains 20 mg telmisartan. 
Üks Telmisartan Teva tablett sisaldab 20 mg telmisartaani.
Each Telmisartan Teva tablet contains 40 mg telmisartan. 
Üks Telmisartan Teva tablett sisaldab 40 mg telmisartaani.
Each Telmisartan Teva tablet contains 80 mg telmisartan. 
Üks Telmisartan Teva tablett sisaldab 80 mg telmisartaani.
There is an apparent trend to a dose relationship to a time to recovery of baseline systolic blood pressure (SBP). 
Esialgse süstoolse vererõhu (SVR) taastumise aeg omab ilmset tendentsi sõltuda annusest.
Back pain (e.g. sciatica), muscle spasms, myalgia 
1 Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 20 mg telmisartan 
TOIMEAINE(TE) SISALDUS Üks tablett sisaldab 20 mg telmisartaani
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 40 mg tablets telmisartan 
RAVIMPREPARAADI NIMETUS Telmisartan Teva 40 mg tabletid telmisartanum
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 80 mg telmisartan 
TOIMEAINE(TE) SISALDUS Üks tablett sisaldab 80 mg telmisartaani
Telmisartan Teva should be used only with caution in patients with mild to moderate hepatic impairment. 
Kerge kuni mõõduka maksakahjustusega patsientidel tuleb Telmisartan Teva't kasutada ettevaatusega.
EU/1/09/610/051 Cartons of 14x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/052 Cartons of 28x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/053 Cartons of 30x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/054 Cartons of 40x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/055 Cartons of 56x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/056 Cartons of 60x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/057 Cartons of 84x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/058 Cartons of 90x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/059 Cartons of 98x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/060 Cartons of 100x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/062 Carton of 30 tablets in aluminium-aluminium blister 
EU/1/09/610/028 Karbid 90x1 tabletiga lahti kooritavates perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/029 Karbid 98x1 tabletiga lahti kooritavates perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/030 Karbid 100x1 tabletiga lahti kooritavates perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/051 Karbid 14x1 tabletiga perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/052 Karbid 28x1 tabletiga perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/053 Karbid 30x1 tabletiga perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/054 Karbid 40x1 tabletiga perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/055 Karbid 56x1 tabletiga perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/056 Karbid 60x1 tabletiga perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/057 Karbid 84x1 tabletiga perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/058 Karbid 90x1 tabletiga perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/059 Karbid 98x1 tabletiga perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/060 Karbid 100x1 tabletiga perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/062 Karp 30 tabletiga alumiinium-alumiinium blistris
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 80 mg tablets telmisartan 
RAVIMPREPARAADI NIMETUS Telmisartan Teva 80 mg tabletid telmisartanum
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 40 mg tablets 
RAVIMPREPARAADI NIMETUS Telmisartan Teva 40 mg tabletid
Hepatic function abnormal/liver disorder 3 
Maksafunktsiooni häire/maksa häire2
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 80 mg tablets 
RAVIMPREPARAADI NIMETUS Telmisartan Teva 80 mg tabletid
Somnolence 
Unisus
Blood and the lymphatic system disorders Uncommon 
Vere ja lümfisüsteemi häired Aeg-ajalt:
EU/1/09/610/041 Cartons of 14x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/042 Cartons of 28x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/043 Cartons of 30x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/044 Cartons of 40x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/045 Cartons of 56x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/046 Cartons of 60x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/047 Cartons of 84x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/048 Cartons of 90x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/049 Cartons of 98x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/050 Cartons of 100x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/09/610/061 Carton of 30 tablets in aluminium-aluminium blister 
EU/1/09/610/021 Karbid 14x1 tabletiga lahti kooritavates perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/022 Karbid 28x1 tabletiga lahti kooritavates perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/023 Karbid 30x1 tabletiga lahti kooritavates perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/024 Karbid 40x1 tabletiga lahti kooritavates perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/025 Karbid 56x1 tabletiga lahti kooritavates perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/026 Karbid 60x1 tabletiga lahti kooritavates perforeeritud üheannuselistes alumiinium-alumiinium blistrites EU/1/09/610/027 Karbid 84x1 tabletiga lahti kooritavates perforeeritud üheannuselistes alumiinium-alumiinium blistrites
Therefore, in these patients an approptiate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required, when indicated. 
Vajalikuks võib osutuda insuliini või diabeedivastaste ravimite annuse kohandamine vastavate näidustuste olemasolul.
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 20 mg tablets 
RAVIMPREPARAADI NIMETUS Telmisartan Teva 20 mg tabletid
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 20 mg tablets telmisartan 
RAVIMPREPARAADI NIMETUS Telmisartan Teva 20 mg tabletid telmisartanum
EU/1/09/610/021 14x1 tablets EU/1/09/610/022 28x1 tablets EU/1/09/610/023 30x1 tablets EU/1/09/610/024 40x1 tablets EU/1/09/610/025 56x1 tablets EU/1/09/610/026 60x1 tablets EU/1/09/610/027 84x1 tablets EU/1/09/610/028 90x1 tablets EU/1/09/610/029 98x1 tablets EU/1/09/610/030 100x1 tablets 
EU/1/09/610/021 14x1 tabletti EU/1/09/610/022 28x1 tabletti EU/1/09/610/023 30x1 tabletti EU/1/09/610/024 40x1 tabletti EU/1/09/610/025 56x1 tabletti EU/1/09/610/026 60x1 tabletti EU/1/09/610/027 84x1 tabletti EU/1/09/610/028 90x1 tabletti EU/1/09/610/029 98x1 tabletti EU/1/09/610/030 100x1 tabletti
EU/1/09/610/041 14x1 tablets EU/1/09/610/042 28x1 tablets EU/1/09/610/043 30x1 tablets EU/1/09/610/044 40x1 tablets EU/1/09/610/045 56x1 tablets EU/1/09/610/046 60x1 tablets EU/1/09/610/047 84x1 tablets EU/1/09/610/048 90x1 tablets EU/1/09/610/049 98x1 tablets EU/1/09/610/050 
EU/1/09/610/041 14x1 tabletti EU/1/09/610/042 28x1 tabletti EU/1/09/610/043 30x1 tabletti EU/1/09/610/044 40x1 tabletti EU/1/09/610/045 56x1 tabletti EU/1/09/610/046 60x1 tabletti EU/1/09/610/047 84x1 tabletti EU/1/09/610/048 90x1 tabletti EU/1/09/610/049 98x1 tabletti EU/1/09/610/050 100x1 tabletti EU/1/09/610/061 30 tabletti
EU/1/09/610/031 14x1 tablets EU/1/09/610/032 28x1 tablets EU/1/09/610/033 30x1 tablets EU/1/09/610/034 40x1 tablets EU/1/09/610/035 56x1 tablets EU/1/09/610/036 60x1 tablets EU/1/09/610/037 84x1 tablets EU/1/09/610/038 90x1 tablets EU/1/09/610/039 98x1 tablets EU/1/09/610/040 100x1 tablets 
EU/1/09/610/031 14x1 tabletti EU/1/09/610/032 28x1 tabletti EU/1/09/610/033 30x1 tabletti EU/1/09/610/034 40x1 tabletti EU/1/09/610/035 56x1 tabletti EU/1/09/610/036 60x1 tabletti EU/1/09/610/037 84x1 tabletti EU/1/09/610/038 90x1 tabletti EU/1/09/610/039 98x1 tabletti EU/1/09/610/040 100x1 tabletti
EU/1/09/610/011 14x1 tablets EU/1/09/610/012 28x1 tablets EU/1/09/610/013 30x1 tablets EU/1/09/610/014 40x1 tablets EU/1/09/610/015 56x1 tablets EU/1/09/610/016 60x1 tablets EU/1/09/610/017 84x1 tablets EU/1/09/610/018 90x1 tablets EU/1/09/610/019 98x1 tablets EU/1/09/610/020 100x1 tablets 
EU/1/09/610/011 14x1 tabletti EU/1/09/610/012 28x1 tabletti EU/1/09/610/013 30x1 tabletti EU/1/09/610/014 40x1 tabletti EU/1/09/610/015 56x1 tabletti EU/1/09/610/016 60x1 tabletti EU/1/09/610/017 84x1 tabletti EU/1/09/610/018 90x1 tabletti EU/1/09/610/019 98x1 tabletti EU/1/09/610/020 100x1 tabletti
EU/1/09/610/001 14x1 tablets EU/1/09/610/002 28x1 tablets EU/1/09/610/003 30x1 tablets EU/1/09/610/004 40x1 tablets EU/1/09/610/005 56x1 tablets EU/1/09/610/006 60x1 tablets EU/1/09/610/007 84x1 tablets EU/1/09/610/008 90x1 tablets EU/1/09/610/009 98x1 tablets EU/1/09/610/010 100x1 tablets 
EU/1/09/610/001 14x1 tabletti EU/1/09/610/002 28x1 tabletti EU/1/09/610/003 30x1 tabletti EU/1/09/610/004 40x1 tabletti EU/1/09/610/005 56x1 tabletti EU/1/09/610/006 60x1 tabletti EU/1/09/610/007 84x1 tabletti EU/1/09/610/008 90x1 tabletti EU/1/09/610/009 98x1 tabletti EU/1/09/610/010 100x1 tabletti
EU/1/09/610/051 14x1 tablets EU/1/09/610/052 28x1 tablets EU/1/09/610/053 30x1 tablets EU/1/09/610/054 40x1 tablets EU/1/09/610/055 56x1 tablets EU/1/09/610/056 60x1 tablets EU/1/09/610/057 84x1 tablets EU/1/09/610/058 90x1 tablets EU/1/09/610/059 98x1 tablets EU/1/09/610/060 
EU/1/09/610/051 14x1 tabletti EU/1/09/610/052 28x1 tabletti EU/1/09/610/053 30x1 tabletti EU/1/09/610/054 40x1 tabletti EU/1/09/610/055 56x1 tabletti EU/1/09/610/056 60x1 tabletti EU/1/09/610/057 84x1 tabletti EU/1/09/610/058 90x1 tabletti EU/1/09/610/059 98x1 tabletti EU/1/09/610/060 100x1 tabletti EU/1/09/610/062 30 tabletti
Pruritus, hyperhidrosis, rash 
Kihelus, liighigistamine, lööve
Muscoloskeletal and connective tissue disorders Uncommon: 
Maksa- ja sapiteede häired Harv:
Summary of the safety profile 
1 - Ravimiohutuse riskihindamise nõuandekomitee teadusliku hindamise üldkokkuvõte
Metabolism and nutrition disorders Uncommon 
Ainevahetus- ja toitumishäired Aeg-ajalt:
36 months 
36 kuud
Other trials gave similar or higher results. 
Teised uuringud andsid samasuguseid või kõrgemaid tulemusi.
Tell your doctor promptly about these symptoms. 
Rääkige neist sümptomitest kohe arstile.
In rare instances, these cases were associated with swelling of the entire limb. 
Harvadel juhtudel olid need juhud seotud kogu jäseme tursega.
Not applicable. 
Ei ole kohaldatav
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION October 23 
ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV 23. oktoober 2000